Follow Us:

social twitter box white 32 social facebook box blue 32social linkedin box blue 32ISN Blog

Friday, 25 December 2015 20:26

Sclerostin levels in CKD patients: an important, but not definitive, step on the way to clinical use (COMMENTARY)

By  Delanaye et al.
Rate this item
(0 votes)

Sclerostin, an inhibitor of the Wnt signaling pathway, inhibits bone formation. In a study of vascular biopsies of patients undergoing kidney transplantation, Qureshi et al. demonstrate that circulating sclerostin levels are associated with vascular calcification (VC). This adds to an emerging body of literature implicating sclerostin as a key link between chronic kidney disease–mineral and bone disorder and cardiovascular disease. Some confounders of this association remain, and the mechanisms by which sclerostin promotes VC have yet to be elucidated.

 Authors: 

Pierre Delanaye, Etienne Cavalier, Antoine Bouquegneau and Arif Khwaja

Reference: 

Kidney Int 88: 1221-1223; doi:10.1038/ki.2015.258

Additional Info

  • Language: English
  • Contains Audio: No
  • Content Type: Articles
  • Source: KI
  • Year: 2015
  • Members Only: No
Read 1071 times

Global Operations Center

Rue des Fabriques 1
1000 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact

               

Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact